About this Product:
This course provides both an overview of non-mammalian expression systems, as well as an in-depth exploration of both Escherichia coli and different strains of yeast as expression platforms. Both Instructors, Dom Esposito of SAIC-Frederick/NIH and Piotr Bobrowicz of Adimab, possess many years of experience with their specific expression host. They share their insights and extensive knowledge to help those in the lab achieve optimized expression.
This digital course is perfect for those who want to learn about using E.coli as an expression system, and for researchers wishing to build and expand their mastery.
About this Product:2 Presentations90 SlidesOver 103 MinutesIndividual: $345Site License: $1380
Agenda At A Glance:
Overview of Protein Expression Systems
Dominic Esposito, Ph.D., Director, Protein Expression Laboratory, Advanced Technology Program, Frederick National Laboratory for Cancer Research (FNL), SAIC-Frederick, Inc.
Protein Production in E. Coli: 21st Century Techniques to Enhance the Utility of a 20th Century Expression Host
As the number of proteins made in eukaryotic hosts continues to increase, we should not lose sight of the power of the simple bacterium, Escherichia coli, for the rapid, inexpensive production of proteins and protein fragments. While E. coli has its limitations, many advances in the past decade have ensured this small organism's place at the table of protein production. This talk will discuss variables such as solubility tags and host strains, optimization of expression conditions, and tricks of the trade that can all improve the chances of high quality production of useful proteins from E. coli. I will also compare and contrast bacterial expression to its eukaryotic companions and discuss when are the right situations for choosing the E. coli system for your protein of interest.
Application of Yeast Cells for Therapeutic Protein Discovery, Optimization and Production
Piotr Bobrowicz, Ph.D., Director, Technology and Platform Development, Adimab, LLC
Yeast cells offer an economical and highly adaptable system for small and large scale production of proteins. During the last decade significant progress has been made in yeast cell engineering and process optimization making yeast strains not only viable, but also competitive alternatives to mammalian cells for the production of human proteins. In the past, fungal post-translational modifications and bottlenecks in folding and secretion were limiting the usefulness of yeast for therapeutic protein production. The introduction of cells with a modified secretory pathway in combination with novel approaches to expression vector optimization overcame several of those limitations. For example, glyco-engineering enabled production of proteins with uniform human glycans. High throughput expression and strain selection methods provided tools for the selection of cell lines with desired characteristics. This talk will provide an overview of the recent improvements with examples of how a yeast protein expression system can be successfully applied to therapeutic protein discovery, optimization and production.
About the Conference:
The Bioprocessing Summit brings together international leaders to discuss today's bioprocess issues from cell line selection to manufacturing. The Summit provides practical details in a relaxed, congenial atmosphere that promotes information exchange and networking. This year, a "Formulation Foci" has been added to delve into protein structure and formulations.
250 First Avenue, Suite 300
Needham, MA 02494
Biological Therapeutic Products
Biomarkers & Diagnostics
Bioprocess & Manufacturing
Clinical Trials & Translational Medicine
Drug & Device Safety
Drug Discovery & Development
IT & Informatics
Technology & Tools For Life Science
Cambridge Healthtech Institute
Cambridge Innovation Institute